Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating ...

For Andrew Hanna, adapting to changing situations on stage teaches him how to adapt to the many challenges in life. The ...

BAKERSFIELD, Calif. (KGET) — Achondroplasia, otherwise known as short-limbed dwarfism, is a condition seen in movies and pop ...

Before Liz announced that her daughter would be average height, her parents Trent and Amber Johnston had their fingers not-so ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.

The high school sports year has come to a close, but a La Costa Canyon High School freshman swimmer is reshaping what is ...

Today's biotech news update includes a dramatic vote on MDMA therapy, record drug shortages, bad(?) news for Biomarin, and a ...